APA (7th ed.) Citation

Dorigo, O., Oza, A., Tanyi, J., Strauss, J., Pejovic, T., Ghamande, S., . . . Rosu, G. (2018). New clinical data from the DeCidE1 trial: Results on DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with advanced recurrent epithelial ovarian cancer. Annals of oncology, 29, x31. https://doi.org/10.1093/annonc/mdy487.018

Chicago Style (17th ed.) Citation

Dorigo, O., et al. "New Clinical Data from the DeCidE1 Trial: Results on DPX-Survivac, Low Dose Cyclophosphamide (CPA), and Epacadostat (INCB024360) in Subjects with Advanced Recurrent Epithelial Ovarian Cancer." Annals of Oncology 29 (2018): x31. https://doi.org/10.1093/annonc/mdy487.018.

MLA (9th ed.) Citation

Dorigo, O., et al. "New Clinical Data from the DeCidE1 Trial: Results on DPX-Survivac, Low Dose Cyclophosphamide (CPA), and Epacadostat (INCB024360) in Subjects with Advanced Recurrent Epithelial Ovarian Cancer." Annals of Oncology, vol. 29, 2018, p. x31, https://doi.org/10.1093/annonc/mdy487.018.